The apparent success of the drug's early trials prompted Martoma to make the Irish biotech Elan and the New Jersey drugmaker Wyeth (now owned by Pfizer ( PFE ) ) his top stock recommendations, said the feds. He allegedly convinced SAC Capital to buy 10 million shares of Elan and 6.8 million shares of Wyeth, then valued at about $700 million.